Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

Elsevier
Publish with us
Video

Clinicalkey AI in action: What are indications for plasma exchange in severe babesiosis

| 2 min read

ClinicalKey AI combines trusted, evidence-based clinical content with conversational search powered by generative AI to support clinicians in delivering high-quality patient care.  Clinicians gain a powerful ally with ClinicalKey AI by providing quick access to trusted clinical knowledge and allowing them to focus on what truly matters, quality patient care. Interested healthcare organizations can contact us today to learn more.  

ClinicalKey AI Query: What are indications for plasma exchange in severe babesiosis

Plasma exchange, also known as exchange blood transfusion, is indicated in severe babesiosis in cases of high-grade parasitemia (10% or more of erythrocytes), severe hemolytic anemia (less than 10 g/dL), pulmonary, renal, or hepatic impairment, and Babesia divergens infection.[1-2]

  • Exchange blood transfusion is used to rapidly decrease parasite burden and clear toxic byproducts from circulation.[1]

  • The procedure can be either partial or complete, depending on the severity of the disease.[1]

  • It is capable of reducing parasitemia by 90%, and limited data suggest early use (within approximately 1.5 days after presentation) of exchange transfusion may prevent organ dysfunction.[1]

  • In addition to antibiotic treatment, partial or complete red cell exchange transfusion should be considered in severely ill patients with parasitemias in excess of 10%, evidence of severe hemolysis, or organ compromise.[3]

  • A systematic review suggests that apheresis may be a useful adjunct in the treatment of patients hospitalized for babesiosis.[4]

  1. Babesiosis.(opens in new tab/window)  Elsevier ClinicalKey  Clinical Overview 

  2. Babesiosis (Babesia).(opens in new tab/window)  Krause, Peter J.  Book Chapter 

  3. Babesiosis and Other Protozoan Diseases.(opens in new tab/window)  Telford, Sam R., Krause, Peter J. In Goldman-Cecil Medicine (pp. 2151). 

  4. Safety and Effectiveness of Apheresis in the Treatment of Infectious Diseases: A Systematic Review.(opens in new tab/window)  Odedra A, Lalloo DG, Kennedy G, Llewellyn S, McCarthy JS.  The Journal of Infection. 2019;79(6):513-520. doi:10.1016/j.jinf.2019.09.014. 

Answer generated on April 2, 2024 

Note: User acknowledges that these materials are provided for use at no charge as part of Elsevier’s efforts to support healthcare providers and patients. The information contained within the website is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill and judgment of healthcare professionals involved in patient care. The content within this page may not be re-used, modified or re-distributed without prior written permission.